Trial Profile

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avexitide (Primary)
Indications Hypoglycaemia
Focus Therapeutic Use
Acronyms PREVENT
Sponsors Eiger BioPharmaceuticals, Inc.

Most Recent Events

08 May 2025 According to an Eiger BioPharmaceuticals, Inc. media release, company plans to present additional data from the Phase 2 PREVENT at the Endocrine Societys annual meeting (ENDO) 2025 on July 12-15 in San Francisco, CA.
10 Jul 2024 Results presented in the Amylyx Pharmaceuticals Media Release.
20 Jun 2022 The primary endpoint Incidence of treatment-emergent adverse events was removed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com